CellSource Co., Ltd. (4880.T)
JPY 844.0
(-1.97%)
JPY 844.0
(-1.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 923.14 Million JPY | -9.3% |
| 2022 | 1.01 Billion JPY | 56.26% |
| 2021 | 651.39 Million JPY | 137.66% |
| 2020 | 274.08 Million JPY | 37.31% |
| 2019 | 199.6 Million JPY | 3.21% |
| 2018 | 193.4 Million JPY | 73.61% |
| 2017 | 111.4 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 156.07 Million JPY | 8.46% |
| 2024 Q1 | 143.9 Million JPY | -41.98% |
| 2024 Q3 | 74.23 Million JPY | -52.44% |
| 2023 Q3 | 265.07 Million JPY | 36.63% |
| 2023 FY | 923.14 Million JPY | -9.3% |
| 2023 Q4 | 248 Million JPY | -6.44% |
| 2023 Q2 | 194.01 Million JPY | -10.2% |
| 2023 Q1 | 216.04 Million JPY | -49.61% |
| 2022 Q4 | 428.71 Million JPY | 52.71% |
| 2022 FY | 1.01 Billion JPY | 56.26% |
| 2022 Q2 | 152.62 Million JPY | -2.02% |
| 2022 Q1 | 155.76 Million JPY | -30.21% |
| 2022 Q3 | 280.73 Million JPY | 83.94% |
| 2021 Q2 | 155.67 Million JPY | 37.62% |
| 2021 Q1 | 113.11 Million JPY | -2.23% |
| 2021 Q3 | 159.41 Million JPY | 2.41% |
| 2021 Q4 | 223.19 Million JPY | 40.01% |
| 2021 FY | 651.39 Million JPY | 137.66% |
| 2020 Q4 | 115.69 Million JPY | 189.7% |
| 2020 Q2 | 40.91 Million JPY | -47.22% |
| 2020 Q1 | 77.52 Million JPY | 43.89% |
| 2020 FY | 274.08 Million JPY | 37.31% |
| 2020 Q3 | 39.93 Million JPY | -2.4% |
| 2019 FY | 199.6 Million JPY | 3.21% |
| 2019 Q4 | 53.88 Million JPY | 0.0% |
| 2018 FY | 193.4 Million JPY | 73.61% |
| 2017 FY | 111.4 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | -140.402% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 275.198% |
| GNI Group Ltd. | 8.09 Billion JPY | 88.595% |
| Linical Co., Ltd. | 338.26 Million JPY | -172.904% |
| Trans Genic Inc. | 4.08 Million JPY | -22498.335% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 164.198% |
| Soiken Holdings Inc. | -662.2 Million JPY | 239.405% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -568.193% |
| AnGes, Inc. | -7.43 Billion JPY | 112.412% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 171.665% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 112.834% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | -394.468% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 218.351% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 180.072% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 176.356% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 213.63% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 385.218% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 175.666% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 164.915% |
| PeptiDream Inc. | 3.03 Billion JPY | 69.592% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 147.621% |
| Ribomic Inc. | -1.02 Billion JPY | 190.13% |
| SanBio Company Limited | -2.64 Billion JPY | 134.915% |
| Healios K.K. | -3.82 Billion JPY | 124.147% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 179.031% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 161.972% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 164.583% |
| StemRIM | -2.02 Billion JPY | 145.655% |
| FunPep Company Limited | -933.41 Million JPY | 198.899% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 208.077% |
| Stella Pharma Corporation | -763.74 Million JPY | 220.87% |
| TMS Co., Ltd. | -960.04 Million JPY | 196.157% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 181.693% |
| Cuorips Inc. | -632.18 Million JPY | 246.024% |
| K Pharma,Inc. | 260.33 Million JPY | -254.605% |
| Takara Bio Inc. | 1.48 Billion JPY | 37.626% |
| ReproCELL Incorporated | -31.41 Million JPY | 3038.539% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -3399.666% |
| StemCell Institute Inc. | 310.98 Million JPY | -196.848% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -544.792% |
| CellSeed Inc. | -846.53 Million JPY | 209.05% |